What did H.C. Wainwright change for United Therapeutics on Feb 26, 2026?

H.C. Wainwright maintained a **Buy** rating on United Therapeutics (UTHR) and raised the price target to **$600** on February 26, 2026, according to StreetInsider.

How should investors read this UTHR analyst rating?

A maintained Buy with a higher price target signals ongoing analyst confidence in United Therapeutics’ pipeline and cash flow. It supports long‑term conviction but does not guarantee short‑term price gains.

Does the update change Meyka AI’s grade for UTHR?

Meyka AI currently rates UTHR with a grade of **A**. The H.C. Wainwright action supports that grade but does not alone drive grade changes without additional data or consensus shifts.

Where can I read the analyst note and get real‑time updates?

The H.C. Wainwright note was reported on StreetInsider on February 26, 2026. For real‑time tracking and Meyka AI analysis, visit the Meyka UTHR page linked in the article.

Analyst Ratings

H.C. Wainwright Maintains Buy on United Therapeutics (UTHR) Feb 2026

ByHuzaifa Zahoor February 27, 2026

H.C. Wainwright maintained a Buy on United Therapeutics Corporation (UTHR) on February 26, 2026, while raising its price target to $600. This UTHR analyst rating action keeps a positive stance on the stock and was published via StreetInsider the same day. The firm’s note leaves the rating unchanged but signals confidence in United Therapeutics’ pipeline and cash generation. Investors should view the maintained Buy and higher price target as continued analyst support amid the stock’s recent move of -6.34% (-$32.05) since the update.